This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants. A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.
The primary objective of this study is to demonstrate that twice daily application of a ceramide dominant emollient reduces the risk of eczema and food allergy, when compared to standard skin management. Secondary objectives are to determine if twice daily application of a ceramide dominant emollient reduces the risk of infants developing allergic sensitisation (as measured by skin prick test); to determine if twice daily application of a ceramide dominant emollient improves infant skin barrier function; to determine the level of parental compliance with a program to build infant skin barrier function; to confirm that a ceramide dominant emollient does not cause adverse effects in infants; to determine the level of compliance required to demonstrate an improvement in infant skin barrier function and to determine if twice daily application of a ceramide dominant emollient influences infant skin microbial colonisation, or skin lipid profile. This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants. A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals. Treatment will be from birth until six months, with a six week, six month and twelve month follow-up. An initial assessment will be performed at baseline which incorporates three surveys, a skin assessment, diary card (which is to be completed weekly and measures compliance), a breast milk sample, guthrie card and tape stripping. The six week and six month assessments entail a skin assessment, survey, compliance check, breast milk sample, tape stripping and guthrie card. Primary outcomes are assessed at the 12 month follow up where in addition to the aforementioned items, a saliva sample will also be taken and skin prick testing and food challenges will be performed when children have a positive SPT to one or more foods..
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
760
Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
Mercy Women's Hospital
Heidelberg, Victoria, Australia
Frances Perry Private Hospital
Parkville, Victoria, Australia
Murdoch Children's Research Institute
Parkville, Victoria, Australia
Royal Women's Hospital
Parkville, Victoria, Australia
Presence of eczema
as assessed using i) the UK working party criteria for eczema and/or ii) blinded investigator observed eczema.
Time frame: 12 months of age.
Confirmed diagnosis of food allergy at 12 months (52 weeks).
This diagnosis is derived from a combination of allergic sensitisation, reaction history and food challenge. A skin prick test to six common allergens will be performed (egg white, cows' milk, peanut, dust mite, cat dander, and rye grass) along with a negative (saline) and a positive (histamine) control. Participants that are sensitised to certain foods (\>=1mm wheal) during the skin prick testing will be given a challenge to determine if they are allergic to those foods. This will be conducted at the MCRI Allergy Clinic under the supervision of a Doctor specifically trained in oral food challenges.
Time frame: 12 months of age
Eczema severity
assessed using the EASI score
Time frame: 12 months of age
Parent report of a community doctor diagnosis of eczema
Time frame: 12 months of age
infant skin barrier function
As assessed by Trans-epidermal water loss (Vapometer)
Time frame: At 6 weeks and 12 months of age
Parental compliance with a program to build infant skin barrier function
as assessed by parental completion of weekly diary cards and weighing of the tubes of study cream at each visit
Time frame: At 6 weeks and 6 months of age.
Adverse events
as assessed by the documentation of any untoward medical occurrence in a participant enrolled into this study
Time frame: From recruitment of infant until final study visit at 12 months of age.
skin microbial colonisation, or skin lipid profile
Assessed using skin swabs at baseline, 6 weeks and 12 months of age
Time frame: At 6 weeks and 6 and 12 months of age
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.